Evidence map›Paper›PMID 41890342›Full record

ReviewFrontiers in human neuroscience2026

Proceedings of the 13th annual deep brain stimulation think tank: the evolving landscape.

Chance R Fleeting, Eduardo M Moraud, Kamil Uğurbil, Doris D Wang, Wolf-Julian Neumann, Andrea A Kühn, Valerie Voon, Victor Pikov, Marie-Laure Welter, Michael D Fox and 22 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in human neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

32 authors.

Chance R FleetingNorman Fixel Institute for Neurological Diseases, University of Florida, Gainesville, FL, United States.
Eduardo M MoraudDepartment of Clinical Neurosciences, University Hospital Lausanne (CHUV), Lausanne, Switzerland.
Kamil UğurbilCenter for Magnetic Resonance Research, Radiology, Medical School, University of Minnesota Twin Cities, Minneapolis, MN, United States.
Doris D WangDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, CA, United States.
Wolf-Julian NeumannMovement Disorder and Neuromodulation Unit, Department of Neurology, Charité-Universitätsmedizin Berlin, Berlin, Germany.
Andrea A KühnMovement Disorder and Neuromodulation Unit, Department of Neurology, Charité-Universitätsmedizin Berlin, Berlin, Germany.
Valerie VoonDepartment of Psychiatry, University of Cambridge, Cambridge, United Kingdom.
Victor PikovMedipace Inc., Pasadena, CA, United States.
Marie-Laure WelterParis Brain Institute, CNRS UMR 7225, INSERM 1127, Sorbonne University, Paris, France.
Michael D FoxDepartment of Neurology, Psychiatry, and Radiology, Center for Brain Circuit Therapeutics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States.
John D RolstonDepartment of Neurosurgery, Mass General Brigham, Harvard Medical School, Boston, MA, United States.
Mahsa MalekmohammadiDepartment of Neurosurgery, University of California, Los Angeles, Los Angeles, CA, United States.
Yagna J PathakNeuromodulation Division, Abbott, Plano, TX, United States.
Lyndahl M HimesNeuromodulation Division, Abbott, Plano, TX, United States.
David GreeneNeuroPace, Inc., Mountain View, CA, United States.
Abbey S Holt-BeckerRestorative Therapies Group Implantables, Research, and Core Technology, Medtronic Inc., Minneapolis, MN, United States.
Gabriel Lázaro-MuñozCenter for Bioethics, Harvard Medical School, Boston, MA, United States.
Alexander W CharneyThe Windreich Department of Artificial Intelligence and Human Health, Mount Sinai Medical Center, New York, NY, United States.
Amanda R MernerCenter for Bioethics, Harvard Medical School, Boston, MA, United States.
Martijn FigeeNash Family Center for Advanced Circuit Therapeutics, Icahn School of Medicine at Mount Sinai, New York, NY, United States.
Katherine W ScangosDepartment of Neurosurgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States.
Timothy DenisonMedical Research Council Brain Network Dynamics Unit, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, United Kingdom.
Kent LeydeCadence Neuroscience, Redmond, WA, United States.
Aysegul GunduzNorman Fixel Institute for Neurological Diseases, University of Florida, Gainesville, FL, United States.
Helen M Bronte-StewartDepartment of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, United States.
James C BeckParkinson's Foundation, New York, NY, United States.
Nora Vanegas-ArroyaveDepartment of Neurology, Baylor College of Medicine, Houston, TX, United States.
Marta San LucianoDepartment of Neurology, University of California, San Francisco, San Francisco, CA, United States.
Norbert BrüggemannInstitute of Neurogenetics, University of Lübeck, Lübeck, Germany.
Kelly D FooteNorman Fixel Institute for Neurological Diseases, University of Florida, Gainesville, FL, United States.
Michael S OkunNorman Fixel Institute for Neurological Diseases, University of Florida, Gainesville, FL, United States.
Joshua K WongNorman Fixel Institute for Neurological Diseases, University of Florida, Gainesville, FL, United States.

Funding

Post-trial Access, Clinical Care, Psychosocial Support, and Scientific Progress in Experimental Deep Brain Stimulation ResearchR01MH133657 · NIMH · MASSACHUSETTS GENERAL HOSPITAL · PI Joseph J. Fins, Gabriel Lazaro-Munoz · 2023 to 2026
$1.9M
NIMH NIH HHS R01 MH133657
6 · The paper itself

Abstract

The Deep Brain Stimulation (DBS) Think Tank XIII was held September 2-4th, 2025, in Gainesville, Florida, at the Norman Fixel Institute for Neurological Diseases at the University of Florida. The theme was "The Evolving Landscape of DBS: New Indications, New Goals." This theme was a continuation of the DBS Think Tank XI and XII, which were focused on emerging technology and pushing the horizon of indications. Since its founding in 2012, the DBS Think Tank has provided a global forum for leading clinicians, engineers, and researchers in both in industry and academia to present, discuss, and debate the current state of DBS technologies as well as to consider important logistics and ethical challenges. Over the course of three days, members of each panel presented and facilitated discussions on the cutting edge of DBS research. The keynote speaker was Dr. Kamil Uğurbil of the University of Minnesota, who led the first group of researchers to demonstrate the feasibility of imaging the human brain using fMRI technology and who was a pioneer in the development of high-field human MRI scanning. Nobel laureate Dr. Stanley Prusiner, from the University of California, San Francisco, used the story of the discovery of prions to demonstrate the power of pursuing a finding even when the idea conflicted with the prevailing state of the field. The think tank was divided into sections, including: Next Generation Neuromodulation for Gait, Brain Networks and Neuromodulation, Neuroscience & Society, Interventional Psychiatry & Behavior, Devices for Closing the Loop, Physiology & Closing the Loop, and A Roadmap for Genetics & Neuromodulation.

Indexed as

closed loop stimulationdeep brain stimulationneuroethicsneurogeneticsNeuromodulation

Identifiers

PMID41890342
PMCPMC13012979

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.